The impact of IL‐6 on CSCs on other prostate cancer cell lines in our panel was measured by FACS, where the fraction of CSCs was measured based on triple‐marker‐positive status (CD44+/CD133+/EpCAM+). The gene discussed is IL6; the disease is prostate carcinoma.